These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 27476144)
21. Quantitative evaluation of each catalytic subsite of cathepsin B for inhibitory activity based on inhibitory activity-binding mode relationship of epoxysuccinyl inhibitors by X-ray crystal structure analyses of complexes. Watanabe D; Yamamoto A; Tomoo K; Matsumoto K; Murata M; Kitamura K; Ishida T J Mol Biol; 2006 Oct; 362(5):979-93. PubMed ID: 16950396 [TBL] [Abstract][Full Text] [Related]
22. Novel beta-lactam derivatives: potent and selective inhibitors of the chymotrypsin-like activity of the human 20S proteasome. Imbach P; Lang M; García-Echeverría C; Guagnano V; Noorani M; Roesel J; Bitsch F; Rihs G; Furet P Bioorg Med Chem Lett; 2007 Jan; 17(2):358-62. PubMed ID: 17095212 [TBL] [Abstract][Full Text] [Related]
23. Crystal structure of cancer chemopreventive Bowman-Birk inhibitor in ternary complex with bovine trypsin at 2.3 A resolution. Structural basis of Janus-faced serine protease inhibitor specificity. Koepke J; Ermler U; Warkentin E; Wenzl G; Flecker P J Mol Biol; 2000 May; 298(3):477-91. PubMed ID: 10772864 [TBL] [Abstract][Full Text] [Related]
24. [Treatment of acute pancreatitis with antitryptic agents. Experimental study and clinical results]. Gillet M; Jaeck D; Sava G; Grenier J; Runser C; Boillot A Therapie; 1971; 26(6):1235-42. PubMed ID: 5146535 [No Abstract] [Full Text] [Related]
25. Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 2. Quan ML; Ellis CD; Liauw AY; Alexander RS; Knabb RM; Lam G; Wright MR; Wong PC; Wexler RR J Med Chem; 1999 Jul; 42(15):2760-73. PubMed ID: 10425087 [TBL] [Abstract][Full Text] [Related]
26. Inhibition activities of natural products on serine proteases. Jedinák A; Maliar T; Grancai D; Nagy M Phytother Res; 2006 Mar; 20(3):214-7. PubMed ID: 16521112 [TBL] [Abstract][Full Text] [Related]
27. Rational design, synthesis, and X-ray structure of selective noncovalent thrombin inhibitors. Wagner J; Kallen J; Ehrhardt C; Evenou JP; Wagner D J Med Chem; 1998 Sep; 41(19):3664-74. PubMed ID: 9733491 [TBL] [Abstract][Full Text] [Related]
28. Structural modification of an orally active thrombin inhibitor, LB30057: replacement of the D-pocket-binding naphthyl moiety. Lee K; Hwang SY; Hong S; Hong CY; Lee CS; Shin Y; Kim S; Yun M; Yoo YJ; Kang M; Oh YS Bioorg Med Chem; 1998 Jun; 6(6):869-76. PubMed ID: 9681152 [TBL] [Abstract][Full Text] [Related]
29. Isolation of potent and specific trypsin inhibitors from a DNA-encoded chemical library. Mannocci L; Melkko S; Buller F; Molnàr I; Bianké JP; Dumelin CE; Scheuermann J; Neri D Bioconjug Chem; 2010 Oct; 21(10):1836-41. PubMed ID: 20806901 [TBL] [Abstract][Full Text] [Related]
30. Urethanyl-3-amidinophenylalanine derivatives as inhibitors of factor Xa. X-ray crystal structure of a trypsin/inhibitor complex and modeling studies. Sperl S; Bergner A; Stürzebecher J; Magdolen V; Bode W; Moroder L Biol Chem; 2000 Apr; 381(4):321-9. PubMed ID: 10839461 [TBL] [Abstract][Full Text] [Related]
31. Comparison of the structures of the cyclotheonamide A complexes of human alpha-thrombin and bovine beta-trypsin. Ganesh V; Lee AY; Clardy J; Tulinsky A Protein Sci; 1996 May; 5(5):825-35. PubMed ID: 8732754 [TBL] [Abstract][Full Text] [Related]
32. Failure of a potent trypsin inhibitor to modify experimental pancreatitis in dogs: p-aminobenzamidine. Geratz JD Arch Surg; 1968 Mar; 96(3):450-7. PubMed ID: 5644121 [No Abstract] [Full Text] [Related]
34. Enantioselective syntheses and biological studies of aeruginosin 298-A and its analogs: application of catalytic asymmetric phase-transfer reaction. Fukuta Y; Ohshima T; Gnanadesikan V; Shibuguchi T; Nemoto T; Kisugi T; Okino T; Shibasaki M Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5433-8. PubMed ID: 15004282 [TBL] [Abstract][Full Text] [Related]
35. Noncovalent inhibition of the serine proteases, alpha-chymotrypsin and trypsin by trifluoro(organo)borates. Smoum R; Rubinstein A; Srebnik M Org Biomol Chem; 2005 Mar; 3(5):941-4. PubMed ID: 15731882 [TBL] [Abstract][Full Text] [Related]
36. Enzymatic synthesis of hyaluronan hybrid urinary trypsin inhibitor. Kakizaki I; Takahashi R; Yanagisawa M; Yoshida F; Takagaki K Carbohydr Res; 2015 Sep; 413():129-34. PubMed ID: 26142361 [TBL] [Abstract][Full Text] [Related]
37. Congeneric but still distinct: how closely related trypsin ligands exhibit different thermodynamic and structural properties. Brandt T; Holzmann N; Muley L; Khayat M; Wegscheid-Gerlach C; Baum B; Heine A; Hangauer D; Klebe G J Mol Biol; 2011 Feb; 405(5):1170-87. PubMed ID: 21111747 [TBL] [Abstract][Full Text] [Related]
38. Computational design of peptide inhibitor based on modifications of proregion from Plutella xylostella midgut trypsin. Jitonnom J; Lomthaisong K; Lee VS Chem Biol Drug Des; 2012 Apr; 79(4):583-93. PubMed ID: 22182282 [TBL] [Abstract][Full Text] [Related]
39. X-ray and neutron protein crystallographic analysis of the trypsin-BPTI complex. Kawamura K; Yamada T; Kurihara K; Tamada T; Kuroki R; Tanaka I; Takahashi H; Niimura N Acta Crystallogr D Biol Crystallogr; 2011 Feb; 67(Pt 2):140-8. PubMed ID: 21245536 [TBL] [Abstract][Full Text] [Related]
40. Free energy calculations show that acidic P1 variants undergo large pKa shifts upon binding to trypsin. Brandsdal BO; Smalås AO; Aqvist J Proteins; 2006 Aug; 64(3):740-8. PubMed ID: 16752417 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]